"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and lifethreatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.
If excessive symptoms of salivation, emesis, urination and defecation occur, the use of Physostigmine Salicylate (physostigmine salicylate (injection)) Injection should be terminated. If excessive sweating or nausea occur, the dosage should be reduced.
Intravenous administration should be at a slow, controlled rate, no more than 1 mg per minute (see DOSAGE). Rapid administration can cause bradycardia, hypersalivation leading to a respiratory difficulties and possible convulsions.
An overdosage of Physostigmine Salicylate (physostigmine salicylate (injection)) Injection can cause a cholinergic crisis.
USAGE IN PREGNANCY: Safe use in pregnancy and lactation has not been established; therefore, use in pregnant women, nursing mothers or women who may become pregnant requires that possible benefits be weighed against possible hazards to mother and child.
Last reviewed on RxList: 11/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Physostigmine Salicylate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.